Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

By Siddhi Mahatole Dec 15 (Reuters) - Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning ...

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.  The Medicines and ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

The latest announcement is out from Tyra Bioscience ( ($TYRA) ). Tyra Biosciences announced the appointment of Bhavesh Ashar as Chief Operating ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

GlobalCapital presents the nominations for its Syndicated Loan, Leveraged Finance and Private Debt Awards 2025. The Awards, ...

The Global Immuno-oncology Clinical Trials Market is expanding steadily due to the rise in cancer incidence, rapid scientific progress in immunotherapy, and growing investments in precision oncology ...